Incentivising innovation in antibiotic drug discovery and development: Progress, challenges and next steps

Journal of Antibiotics

Volumn 70, Issue 12, 2017, Pages 1087-1096

  Simpkin, Victoria L ^a   Renwick, Matthew J ^a   Kelly, Ruth ^a   Mossialos, Elias ^a,b  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

DRUG INDUSTRY; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; FUNDING; HUMAN; MARKET; PRIORITY JOURNAL; PUBLIC HEALTH; RESEARCH; REVIEW; SCIENCE; UNITED KINGDOM; UNITED STATES; ANTIBIOTIC RESISTANCE; DRUG DEVELOPMENT; ECONOMICS; FINANCIAL MANAGEMENT; GOVERNMENT; PROCEDURES;

ANTI-BACTERIAL AGENTS; CAPITAL FINANCING; DRUG DISCOVERY; DRUG INDUSTRY; DRUG RESISTANCE, BACTERIAL; GOVERNMENT PROGRAMS; HUMANS; PUBLIC HEALTH;

EID: 85038610198     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2017.124     Document Type: Review

References (54)

1. The Review on Antimicrobial Resistance. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations, London UK, 1-20, https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the% 20health%20and%20wealth%20of%20nations-1.pdf (2014).
2. Rex, J. H., et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis. 13, 269-275 (2013).
3. Outterson, K., Powers, J. H., Daniel, G. W. & McClellan, M. B. Repairing the broken market for antibiotic innovation. Health Aff. (Millwood) 34, 277-285 (2015).
4. Spellberg, B. The future of antibiotics. Crit. Care 18, 228 (2014).
5. The Boston Consulting Group. Breaking through the wall: Enhancing research and development of antibiotics in science and industry, Berlin DE, 1-84, https://www. bundesgesundheitsministerium.de/fileadmin/Dateien/5-Publikationen/Gesundheit/Berichte/GUARD-Follow-Up-Report-Full-Report-final.pdf (2017).
6. Antibiotics Currently in Clinical Development http://www.pewtrusts.org/~/media/assets/2017/05/antibiotics-currently-in-clinical-development-03-2017.pdf?la=en (2017).
7. Stern, S., C., S., Franken, L., Voller, S., Rentmeister, H. & Grosch, B. A Call for Concerted Action on Antibiotics Research and evelopment, The Boston Consulting Group, Berlin, (2017).
8. Renwick, M. J., Simpkin, V. & Mossialos, E. Targeting innovation in antibiotic drug discovery and development: The need for a one-health, one-Europe, one-world framwork. European Observatory on Health Systems and Policies, London, UK, Health Policy Series No. 45, 1-133, ISBN 9789289050401 (2016).
9. Butler, M. S., Blaskovich, M. A. & Cooper, M. A. Antibiotics in the clinical pipeline in 2013. J. Antibiot. (Tokyo) 66, 571-591 (2013).
10. Chopra, I., et al. Treatment of health-care-associated infections caused by Gramnegative bacteria: A consensus statement. Lancet Infect. Dis. 8, 133-139 (2008).
11. BEAM Alliance. BEAM Alliance position paper: Key actions to reinvigorate investment and R&D in the antibacterial field now, Paris FR, 1-9, https://beam-alliance.eu/assets/2015-Position-Paper.pdf (2015).
12. Mendelson, M., et al. A global antimicrobial conservation fund for low-A nd middleincome countries. Int. J. Infect. Dis. 51, 70-72 (2016).
13. Political Declaration of the high-level meeting of the General Assembly on antimicrobial resistance http://www.un.org/ga/search/view-doc.asp?symbol=A/71/L.2&referer=/english/& Lang=E (2016).
14. Interagency Coordination Group on Antimicrobial Resistance. https://www.un.org/sg/en/content/sg/personnel-appointments/2017-03-17/interagency-coordination-group-antimicrobial-resistance (2017).
15. Renwick, M. J., Brogan, D. M. & Mossialos, E. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. J. Antibiot. (Tokyo) 69, 73-88 (2016).
16. Joint Programming Initiative on Antimicrobial Resistance, http://www.jpiamr.eu (2017).
17. First Joint Call: Innovative approaches to address antibacterial resistance http://www. jpiamr.eu/activities/joint-calls/first-joint-callresult/(2014).
18. Global Antibiotic Research & Development Partnership (GARDP), http://www.dndi.org/diseases-projects/gardp/(2017).
19. CARB-X, http://www.carb-x.org (2017).
20. Outterson, K., et al. Accelerating global innovation to address antibacterial resistance: Introducing CARB-X. Nat. Rev. Drug Discov. 15, 589-590 (2016).
21. US Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013, Atlanta US, 1-114, https://www.cdc.gov/drugresistance/threatreport-2013/index.html (2013).
22. CARB-X. CARB-X injects up to $48 million to accelerate first powered by CARB-X portfolio of drug discovery and development projects to tackle antibiotic resistance http://www.carb-x.org/press (2017).
23. European and Developing Countries Clinical Trials Partnership. Annual Report 2014, The Hague NL, 1-76, http://www.edctp.org/annualreport2014/EDCTP-Annual-Report-2014---EN.pdf (2014).
24. The Review on Antimicrobial Resistance. Tackling a global health crisis: Initial steps, London UK, 1-22, https://amr-review.org/sites/default/files/Report-52.15.pdf (2015).
25. UK-China ties flourish at 2016 High Level People to People Dialogue, https://www.gov. uk/government/news/uk-china-ties-flourish-at-2016-high-level-people-to-people-dialogue (2016).
26. EC. Antimicrobial drug resistance https://ec.europa.eu/research/health/index.cfm?pg= area&areaname=amdr (2017).
27. Kelly, R., Zoubiane, G., Walsh, D., Ward, R. & Goossens, H. Public funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: A systematic observational analysis. Lancet Infect. Dis. 16, 431-440 (2016).
28. EC. Better use of antibiotics-1 million euros, http://ec.europa.eu/research/horizonprize/index.cfm?prize=better-use-antibiotics (2017).
29. Kostyanev, T., Bonten, M. J., O'Brien, S. & Goossens, H. Innovative medicines initiative and antibiotic resistance. Lancet Infect. Dis. 15, 1373-1375 (2015).
30. Kostyanev, T., et al. The innovative medicines initiative's new drugs for bad bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. J. Antimicrob. Chemother. 71, 290-295 (2016).
31. Drive-AB Official Website, http://drive-ab.eu/.
32. European Investment Bank. InnovFin Infectious Disease, http://www.eib.org/attachments/documents/innovfin-infectious-diseases-flysheet-en.pdf (2015).
33. Brogan, D. M. & Mossialos, E. A critical analysis of the review on antimicrobial resistance report and the infectious disease financing facility. Global Health 12, 8 (2016).
34. Billington, J. K. The ABCs of the US Broad Spectrum Antimicrobials Program: Antibiotics, biosecurity, and congress. Health Secur. 13, 349-354 (2015).
35. Eichberg, M. J. Public funding of clinical-stage antibiotic development in the United States and European Union. Health Secur. 13, 156-165 (2015).
36. Office of the Assistant Secretary of Preparedness and Response. HHS forms strategic alliance to develop new antibiotics approach provides a pipeline of new drugs rather than a single medical countermeasure. US Department of Health and Human Services, http://www.phe.gov/Preparedness/news/Pages/strategic-alliance-130522.aspx (2013).
37. Office of the Press Secretary, The White House. Executive Order No. 13676-Combating Antibiotic-Resistant Bacteria (2014).
38. MRC Tackling AMR-a cross-council initiative. https://www.mrc.ac.uk/research/initiatives/antimicrobial-resistance/tackling-amr-a-cross-council-initiative/(2016).
39. RCUK. Global Challenge Research Fund http://www.rcuk.ac.uk/funding/gcrf/(2017).
40. Newton Fund. http://www.newtonfund.ac.uk (2017).
41. National Institute for Health Research. Antimicrobial resistance http://www.nihr.ac.uk/research-and-impact/research-priorities/antimicrobial-resistance.htm.
42. Transatlantic Taskforce on Antimicrobial Resistance. Recommendations for future collaboration between the US and EU, Atlanta US, 1-86, https://www.cdc.gov/drugresistance/pdf/tatfar-progress-report-2014.pdf (2014).
43. Pew Charitable Trusts. GAIN: How a new law is stimulating the development of antibiotics http://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2013/11/07/gain-how-a-new-law-is-stimulating-the-development-of-antibiotics/(2013).
44. Pew Charitable Trusts. LPAD: A regulatory pathway to develop antibiotics and fight drugresistant infections http://www.pewtrusts.org/en/research-and-analysis/q-and-a/2015/06/lpad-a-regulatory-pathway-to-develop-antibiotics-and-fight-drug-resistant-infections (2015).
45. Mossialos, E., Edwards, M. C., Berenson, S., Gemmill-Toyama, J. & Brogan, M. D. Policies and Incentives for Promoting Innovation in Antibiotic Research (World Health Organisation, London, UK, 2010).
46. Monnet, D. L. Antibiotic development and the changing role of the pharmaceutical industry. Int. J. Risk Saf. Med. 17, 133-145 (2005).
47. Ferraro, J. S., Towse, A. & Mestre-Ferrandiz, J. Incentives for New Drugs to Tackle Anti-Microbial Resistance, Office of Health Economics (London, UK, 2017).
48. The Review on Antimicrobial Resistance. Securing new drugs for future generations: The pipeline of antibiotics, London UK, 1-44, https://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS% 20FINAL%20WEB-0.pdf (2015).
49. Brogan, D. M. & Mossialos, E. Incentives for new antibiotics: The Options Market for Antibiotics (OMA) model. Global Health 9, 58 (2013).
50. Rex, J. H. & Outterson, K. Antibiotic reimbursement in a model delinked from sales: A benchmark-based worldwide approach. Lancet Infect. Dis. 16, 500-505 (2016).
51. O'Neill, J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations (2016).
52. Hoffman, S. J., et al. Strategies for achieving global collective action on antimicrobial resistance. Bull. World Health Organ 93, 867-876 (2015).
53. WHO. Global Priority List of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics, 1-7 (World Health Organisation, 2017).
54. Kesselheim, A. & Outterson, K. Improving antibiotic markets for long term sustainability. Yale J. Health Pol. Law Ethics 11, 101-168 (2013).